PATENT CLAIM ANALYSIS

Application Number: 16106121
Application Type: Utility
Filing Date: 2018-08
Publication Date: 2018-12
Patent Classification: ["514", "456000"]

Abstract:
Provided is a novel medicament capable of reducing the side effects of metformin or a pharmaceutically acceptable salt thereof and useful as an anti-malignant tumor agent, in which metformin or a pharmaceutically acceptable salt thereof and dihydroquercetin or a pharmaceutically acceptable salt thereof are combined.

Claim (Index 28):
A method of reducing the side effects of metformin or a pharmaceutically acceptable salt thereof, comprising administering dihydroquercetin or a pharmaceutically acceptable salt thereof to a patient with a malignant tumor.

Metadata:
- Claim Count in Document: 5.0
- Percentile: 96.0
- Lexical Diversity: 1.51613
- Patent Class: 514.0
- Transitional Phrase Type: open
- Component Type: 1
- Foreign Priority: True
- Related Applications: ['14893127', '15723369', '13813916', '15528348', '14009320']

Analysis Scores:
- 35 USC 101 Eligibility (BERT): 0.7358876083921129
- 35 USC 102 Novelty (BERT): 0.548098121177446
- Combined Prediction Score: 0.7171086596706462
- Mean Citation Score: 264.110866
- Max Citation Score: 407.17407
- Similarity Product: 310.40137104662057

Labels:
- Claim Label 101: 1
- Claim Label 102: 1
- Claim Label 103: 0
- Claim Label 112: 1
- Combined Label: 1
- Label 101 Adjusted: 1

Dataset: test